134
Views
11
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects

Evaluation of: Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009;69:4309-18

&
Pages 311-314 | Published online: 05 Jan 2010

Bibliography

  • Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor–transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24:419-24
  • Wada S, Yoshimura K, Hipkiss EL, Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009;69:4309-18
  • Ercolini AM, Ladle BH, Manning EA, Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J Exp Med 2005;201:1591-602
  • Machiels JP, Reilly RT, Emens LA, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor–secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97
  • Emens LA, Armstrong D, Biedrzycki B, A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF–secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 2004;15:313-37
  • Emens LA, Asquith JM, Leatherman JM, Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF–secreting breast tumor vaccine. J Clin Oncol 2009;27:5911-8
  • Laheru D, Lutz E, Burke J, Allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-63
  • Higano C, Saad F, Somer B, A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp, Orlando, FL, USA, 26-28 Feb 2009; abstract LBA150
  • Small E, Demkow T, Gerritsen WR, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp, Orlando, FL, USA, 26-28 Feb 2009; abstract 7
  • Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.